<DOC>
	<DOC>NCT01671774</DOC>
	<brief_summary>The purpose of the trial is to assess the immunological effects and their kinetics, the safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of Interleukin-2 in subjects with advanced gastroesophageal cancer.</brief_summary>
	<brief_title>Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction Inoperable locally advanced disease, resections with R0, R1 or R2 outcome or metastatic disease. CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor tissue sample. Measurable and/or nonmeasurable disease as defined according to RECIST v1.1 Age â‰¥ 18 years Written informed consent ECOG performance status (PS) 01 Life expectancy &gt; 3 months Prior hypersensitivity reaction or intolerance to one of the compounds of the study treatment Known HIV infection or known symptomatic hepatitis (A, B, C) Clinical symptoms of cerebral metastases Pregnancy or breastfeeding Patients treated with any bisphosphonatebased therapeutic for any indication during the previous year Hypocalcemia that requires medication. Corrected (adjusted for serum albumin) serum calcium &lt; 8 mg/dl (2 mmol/L) or &gt; 12 mg/dL (3.0 mmol/L)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>